# A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

> **NCT01701882** · PHASE3 · COMPLETED · sponsor: **St Stephens Aids Trust** · enrollment: 40 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** tenofovir/emtricitabine/rilpivirine

## Key facts

- **NCT ID:** NCT01701882
- **Lead sponsor:** St Stephens Aids Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701882, "A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01701882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*